Juridical Foundation the Chemo-sero-therapeutic Research Institute

Km Biologics Co., Ltd.

Yoichiro Kino

Nobuya Ohtomo

Keiichi Makizumi

Chikateru Nozaki

Sachio Tokiyoshi

Kazuhiko Kimachi

Hiroshi Nakatake

Hiroshi Yonemura

Tatsuo Eto

Katsuhiko Fukada

Kanako Masuda

Makoto Moriyama

Yuki Mihara

A method for preparing a PRP conjugate having high storage stability and a method for producing a Hib conjugate vaccine are provided. A method for preparing PRP conjugate in accordance with the embodiments of the present invention is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP for a coupling reaction between PRP and a carrier protein. Also, a Hib conjugate vaccine comprising as an antigen the PRP conjugate prepared by said method has excellent storage stability and maintain sufficient immunogenicity.

Method for producing Hib conjugate vaccine using PRP with lowered molecular weight

A novel MDCK-derived cell line (B-702) is provided that can be grown in the absence of fetal calf serum and in suspension culture for allowing a tank culture on the production scale and needs no carrier in suspension culture, as well as a process for producing virus for vaccine by using said cell line in a low-cost, highly safe and stable manner.

Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

A novel recombinant plasmid inserted with a herpes simplex virus gene, which comprises a plasmid vector containing a yeast DNA sequence and an Escherichia coli DNA sequence and carrying a promoter region and a herpes simplex virus gN gene (HSVgB) gene) recombined thereto under control of the promoter, said HSVgB gene lacking an N-terminal portion of the gene including a signal sequence-encoding region and optionally further lacking the region downstream therefrom, such as a gB gene lacking a DNA sequence encoding the N-terminal 30 amino acids, and a gB gene lacking a DNA sequence encoding the N-terminal 83 amino acids. The recombinant plasmid is useful for the production of transformed yeast, which is useful for the production of HSVgB proteins suitable for producing HSV vaccine and diagnostic reagents for herpes simplex virus infections.

Recombinant plasmid inserted with herpes simplex virus gene

An improved herpes simplex virus subunit vaccine being effective against both of HSV type 1 and type 2 and having high safety and high effectiveness, which comprises as an active component a highly purified glycoprotein gB which is a component common to Herpes simplex virus type 1 and type 2, and a method for preparing the herpes simplex virus subunit vaccine and also a lyophilized preparation of the vaccine.

Herpes simplex virus subunit vaccine

Growing community of inventors

Kumamoto, Japan

Yoichiro Kino